Inhibitors of renal sodium-glucose cotransporter type 2 (SGLT2) are a new class of antidiabetic drugs that have recently been introduced into clinical practice for the treatment of patients with type 2 diabetes mellitus. According to CREDENCE study, the inclusion of canagliflozin in drug therapy for patients with type 2 diabetes mellitus not only provides adequate control of blood glucose but also has a pronounced nephroprotective effect, which manifests in a significant reduction in the risk of progression of renal dysfunction in patients with stages 2, 3a and 3b CKD. The identification of nephroprotective effects in SGLT2 inhibitors, which is not related to their antihyperglycemic effect, suggests the possibility of using drugs of this class for drug therapy of patients with CKD of non-diabetic etiology. The review presents the data of clinical studies devoted to elucidating the participation of diuretic action and the associated decrease in blood pressure and venous stasis in the kidneys, improving glomerular hemodynamics and inhibiting the activity of intrarenal RAS in the mechanism of nephroprotective action of these drugs. Large-scale DAPA-CKD and EMPA-KIDNEY studies are currently underway, the results of which will provide information on the clinical efficacy and safety of dapagliflozin and empagliflozin in non-diabetic patients with the impaired renal function of varying severity, including those with stage 4 CKD. Initial data obtained in the DAPA-CKD trial indicated that dapagliflozin, when added to nephroprotective therapy, significantly improves renal outcomes not only in patients with type 2 diabetes but also in patients with CKD of non-diabetic origin, including those with glomerulonephritis, hypertensive nephropathy, and other kidney damage.
30 April 2024 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
The inclusion of spironolactone in antihypertensive therapy does not provide blood pressure (BP) control in the significant proportion of patients with resistant hypertension (HTN) and is accompanied by an increased risk of developing of hyperkalemia and complications associated with blockade of male and female sex hormone receptors. In this regard, a search is underway for new drugs that are not only capable of effectively controlling BP in this population, but also have a more favorable safety profile than their predecessors. The most promising are new drugs that selectively suppress the activity of aldosterone synthase-aldosterone-mineralcorticoid receptor hormonal system, the excessive activity of which underlies the formation of resistant HTN. The review presents data on the characteristics of pharmacokinetics and the results of the clinical studies obtained in patients with resistant HTN when assessing the effectiveness and safety of the use of the new nonsteroidal mineralcorticoid receptor antagonist finerenone and the selective aldosterone synthase inhibitor baxdrostat.
4 August 2021 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Improving the effectiveness of drug therapy and reducing the risk of adverse cardiovascular and renal outcomes in patients with resistant hypertension (HTN) remains an unsolved problem of cardiology. The results of the PATHWAY-2, PATHWAY-3 and ReHOT studies have shown the clinical efficacy of spironolactone, amiloride and, to a lesser extent, the antiadrenergic drugs clonidine, bisoprolol and doxazosin in improving blood pressure (BP) control in this patient population. However, the inclusion of spironolactone and other known drugs in antihypertensive therapy does not ensure the achievement of target BP level in a significant proportion of these patients. The review presents the results of clinical studies of new approaches aimed at increasing the effectiveness of drug therapy in resistant HTN including sodium-glucose cotransporter type 2 inhibitors, brain aminopeptidase A inhibitors, and new antagonists of endothelin receptors.
17 September 2024 in Nephrology (Saint-Petersburg)
The hormonal system aldosterone synthase-aldosterone-mineralcorticoid receptor plays a key role in kidney damage, progression of CKD and increased blood pressure in patients with diabetic and nondiabetic nephropathy. The steroid antagonist of mineralcorticoid (MC) receptors spironolactone and its replacement eplerenone are recommended to be included in combination with RAS inhibitors to control blood pressure and reduce urinary protein loss in hypertensive patients with stages C1-C3a of CKD. However, the use this drugs in CKD is limited due to the risk of hyperkalemia, gynecomastia and other unwanted side effects. Recently, a new generation of MC receptor antagonists has been developed, which differ from its predecessors in a different mechanism of action, improved pharmacological properties and a more favorable safety profile. The review presents data on the pharmacokinetics and pharmacodynamics of the new nonsteroidal MC receptor antagonist finerenone, as well as the results of clinical studies obtained in assessing its effectiveness and safety in patients with CKD diabetic and nondiabetic origin.
Amlodipine and selective dihydropyridine Ca2+ channels blockers of the second generation in addition to ACE inhibitors or replacing them antagonists of AT1-angiotensin receptors don’t improve clinical renal outcomes in hypertensive patients with chronic kidney disease. These drugs don’t eliminate intraglomerular hypertension that underlies hypertensive nephropathy and can have an adverse effect on the neurohormonal status of the organism, triggering the activation of the sympathetic and renin-angiotensin-aldosterone systems. The review presents the results of clinical studies evaluating the effectiveness of the use in this patients population of a new dihydropyridine blocker L-Ca2+ channels third-generation lercanidipine, dual blocker T/L-Ca2+ channels benedipine and dual blocker N/L-Ca2+ channels cilnidipine, that differ from their predecessors expressed renoprotective properties.
23 September 2024 in Rational Pharmacotherapy in Cardiology
Resistant arterial hypertension is characterized by failure to control target blood pressure despite long-term use of optimal or maximum tolerated doses of three different antihypertensive drugs, including diuretic. Patients with resistant hypertension are included in a group of people at high risk of cardiovascular and renal complications, including accelerated progression of chronic kidney disease with a more rapid transition to the final stage of the disease. Resistant hypertension is based on a salt-sensitive, volume-dependent form of hypertension, which usually occurs against the background of increased aldosterone production and normal or even decreased renin plasma activity. A key role in its formation is played by an increase of sodium reabsorption in the kidneys, associated with excessive activity of aldosterone-sensitive epithelial sodium channels (ENaC), which control the reabsorption of this ion in the distal segments of the nephron. Its assumed that in this pathological process, in addition to aldosterone, is also involved the small Rho GTFase Rac1 — regulatory G-protein, which can enter into a direct ligand-independent interaction with mineralcorticoid receptors, performing the function of a powerful nonsteroidal activator of the transmission of their intracellular signals. Based on controlled, randomized clinical trials, the optimal fourth drug to overcome resistance in such patients is the steroid mineralcorticoid receptor antagonist spironolactone. However, the inclusion of this drug in antihypertensive therapy not only fails to control blood pressure in a significant proportion of patients with resistant hypertension, but also significantly increases the risk of hyperkalemia, especially in people with impaired renal function. The review presents data on the pharmacodynamics and pharmacokinetics of new inhibitors of aldosterone synthase-aldosterone-mineralocorticoid receptor hormonal system baxdrostat and finerenone, as well as the results of clinical studies assessing the clinical effectiveness and safety profile of these drugs in patients with resistant hypertension.